.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA02_Granisetron.Granisetron .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA02_Granisetron.Granisetron| name: | Granisetron |
| ATC code: | A04AA02 | route: | intravenous |
| n-compartments | 2 |
Granisetron is a selective 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and, to a lesser extent, postoperatively. It is an FDA-approved drug and is used clinically worldwide.
Pharmacokinetic parameters are for healthy adult volunteers after intravenous administration. Typical dose is a single intravenous bolus injection.
Nakade, S, et al., & Miyata, Y (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer chemotherapy and pharmacology 63(1) 75–83. DOI:10.1007/s00280-008-0713-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/18317761
Woo, JS (2007). Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. Archives of pharmacal research 30(6) 778–784. DOI:10.1007/BF02977642 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17679558
Fox-Geiman, MP, et al., & Stiff, P (2001). Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 7(11) 596–603. DOI:10.1053/bbmt.2001.v7.pm11760147 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11760147